Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

BASEL, Switzerland and BRISBANE, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

RG7227/ ITMN-191 is being developed in partnership by Roche and InterMune. Initiation of the Phase 2b trial triggered a $20 million event payment from Roche to InterMune under the companies' collaboration agreement.

Frank Duff, M.D., Head of Roche's Clinical Development for Virology, said, "This trial represents an important step forward in the development of this oral direct-acting antiviral (DAA), and builds on the encouraging clinical safety and efficacy data generated to date."

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased to announce with our colleagues, Roche, the start of the global Phase 2b program of RG7227/ ITMN-191 in treatment-naive HCV patients. This study will significantly expand the clinical efficacy and safety database for RG7227/ ITMN-191, and in the first quarter of next year provide our first look at the rapid virologic response (RVR) rates associated with this triple therapy."

Phase 2b Triple Combination Trial Design

Th
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... 22, 2014 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... who allegedly developed Type 2 diabetes due to its ... litigation now underway in U.S. District Court, District of ... documents, the litigation will convene its next Status Conference ... directed Lead Counsel for Plaintiffs and Defendants to meet ...
(Date:11/22/2014)... 22, 2014 The Sports Conflict Institute ... Baroff to its team of conflict resolution professionals. Baroff ... coach, and referee. He has over 30 years experience as ... , “I'm very excited to connect with SCI and bring ... interests to a program with a complete sports focus,” says ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... are better when patients are treated in an ambulance by ... German researchers report. The sooner patients get the clot ... outcome after a stroke, the researchers noted. For the best ... hour after stroke symptoms start, the researchers said. "The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... ubiquitous and pedestrian drugs -- aspirin -- may cut the ... has not yet spread beyond the gland, a new study ... 5,000 men with prostate cancer, 2,000 of whom were taking ...
... prostate cancer treated with a specialized type of ... fewer gastrointestinal complications compared to patients treated with ... study presented November 1, 2010, at the 52nd ... Oncology (ASTRO). , "With survivors living ...
... chemotherapy to radiation therapy for muscle invasive bladder cancer allows ... their bladders two years after treatment. This compares to 54 ... largest randomized study of its kind presented at the plenary ... the American Society for Radiation Oncology (ASTRO). , "The trial ...
... October 25, 2010 The Life Sciences Discovery Fund (LSDF) ... Corporation (NASDAQ: OMER) to discover, develop, and commercialize new ... successful generation of proceeds through partnering and the sales ... the grant would be establishment of a new non-profit ...
... By Serena Gordon HealthDay Reporter , MONDAY, Oct. ... to sleep-starved parents: Most infants will start sleeping through the ... may take a little longer, however, is for the baby,s ... schedule, according to the study. "The most rapid changes ...
... PICK: Pregnancy outcome affected by immune system genes ... Moffett, at the University of Cambridge, United Kingdom, has ... to and provide protection from common disorders of pregnancy, ... A key step in the initiation of a successful ...
Cached Medicine News:Health News:Aspirin May Help Patients Beat Prostate Cancer 2Health News:Aspirin May Help Patients Beat Prostate Cancer 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Chemotherapy plus radiation prevents bladder cancer recurrences 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 2Health News:Most Babies Start Sleeping Through Night at 2 to 4 Months 3Health News:JCI table of contents: Oct. 25, 2010 2Health News:JCI table of contents: Oct. 25, 2010 3Health News:JCI table of contents: Oct. 25, 2010 4Health News:JCI table of contents: Oct. 25, 2010 5Health News:JCI table of contents: Oct. 25, 2010 6Health News:JCI table of contents: Oct. 25, 2010 7Health News:JCI table of contents: Oct. 25, 2010 8Health News:JCI table of contents: Oct. 25, 2010 9
(Date:11/21/2014)... and VIENNA, Va. , Nov. 21, ... provider that operates in Southern California ... of remote caregiving technology. Alta will be providing the ... receiving homecare services. Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... the key to providing the kind of affordable 24/7 ...
(Date:11/21/2014)... , Nov. 21, 2014   Rock Creek ... that the Company is scheduled to present at the ... Francisco, CA on January 12-14, 2015. ... and CEO of Rock Creek Pharmaceuticals, will present preclinical ... cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan ...
(Date:11/21/2014)... UNION CITY, Calif. , Nov. 21, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... the completion of a stock purchase agreement to acquire ... United Kingdom based distribution organization. The ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... The National Association of Public Hospitals ... exclusive online community for employees at its member hospitals, becoming ... year-round Within3 online collaborative community. For the first ... regional and local issues in an online forum, enabling continuous ...
... 2011 Amended 13D for RepliGen Corporation ... Chez, a private investor. Mr. Ronald L. Chez ... investor. RepliGen Corporation is a biopharmaceutical company focused on ... deliver the benefits of protein therapies in the fields of neurology ...
Cached Medicine Technology:National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3 2National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3 3
Surgical Drop-Off Apron...
All Day Comfort for the Upper Body...
All Day Comfort for the Upper Body...
Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....
Medicine Products: